UK markets closed

Apogee Therapeutics, Inc. (APGE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
42.12-1.73 (-3.96%)
At close: 04:00PM EDT
42.86 +0.74 (+1.77%)
After hours: 04:44PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close43.85
Open43.65
Bid42.03 x 100
Ask42.20 x 300
Day's range41.95 - 43.73
52-week range14.19 - 72.29
Volume333,608
Avg. volume586,820
Market cap2.374B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD

    SAN FRANCISCO and WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today announced that Lisa Bollinger, MD, has been appointed to the company’s board of directors. Dr. Bollinger most recently served as Vice President, Regulatory Affairs, Glob

  • GlobeNewswire

    Apogee Therapeutics to Participate in Upcoming June Investor Conferences

    SAN FRANCISCO and WALTHAM, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, COPD, asthma and other inflammatory and immunology indications, today announced that members of management will participate at the following upcoming investor conferences: Jefferies Global Healthcare Conference Date: Thursday, June 6, 2024Time: 8:30 a.m. ET Goldman Sachs 45th

  • GlobeNewswire

    Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

    Interim clinical data from APG777 Phase 1 healthy volunteers study exceeded all trial objectives and achieved a half-life of approximately 75 days with a potentially best-in-class profile 16-week proof-of-concept data from Part A of the Phase 2 trial expected in 2H 2025 Pipeline-in-a-product potential with a Phase 2 in asthma expected to initiate in 2025 and plans for additional indication expansion SAN FRANCISCO and WALTHAM, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nas